{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:22:31Z","timestamp":1777879351929,"version":"3.51.4"},"reference-count":33,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["24mk0121274h0002"],"award-info":[{"award-number":["24mk0121274h0002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Drug Safety"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Methotrexate (MTX) is commonly prescribed for pediatric inflammatory diseases. However, clinical data on MTX-induced liver injury in children with rare inflammatory diseases currently remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To examine the association between MTX treatment and abnormal liver function in children with inflammatory diseases and to characterize the clinical course of suspected MTX-induced liver injury cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>A self-controlled case series analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This study was conducted on children aged &lt;15\u2009years with juvenile idiopathic arthritis, psoriasis, or inflammatory bowel disease between April 2016 and March 2024. Data were obtained from the Pediatric Medical Information Collection System database, which integrates electronic medical records from over 40 pediatric medical institutions in Japan. The risk period was defined as the 7-day interval following MTX administration. In addition, this analysis compared the incidence of outcomes during the risk period with the baseline period within the same individuals. The outcome was alanine aminotransferase (ALT) elevation, defined as serum ALT levels exceeding three times the upper limit of normal. The age-adjusted incidence rate ratio (aIRR) was calculated, and clinical courses were assessed following ALT elevation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Among 3696 children with inflammatory diseases, 587 received MTX treatment, while 81 developed abnormal ALT elevation. An increased risk of ALT elevation was observed (aIRR: 2.27, 95% confidence interval: 1.45\u20133.55). Among 45 patients with ALT elevation observed during the risk period, the normalization occurred in 35 patients. The 11 patients experienced a relapse of ALT elevation, while no patients receiving folic acid supplementation showed a relapse of ALT elevation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Methotrexate treatment in children with inflammatory diseases increases the risk of liver enzyme elevation, highlighting the necessity of liver function monitoring. Folic acid supplementation may help mitigate the exacerbation of MTX-induced liver injury in pediatric patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20420986251392451","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T11:17:33Z","timestamp":1762946253000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Methotrexate use and risk of abnormal alanine aminotransferase elevation in children with rare inflammatory diseases: a self-controlled case series analysis using a pediatric electronic health record database in Japan"],"prefix":"10.1177","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0324-6084","authenticated-orcid":false,"given":"Masayoshi","family":"Nakakuni","sequence":"first","affiliation":[{"name":"Department of Multicenter Collaboration, Center for Clinical Research and Development, National Center for Child Health and Development, Okura, Setagaya-ku, Tokyo 157-8535, Japan"},{"name":"Laboratory of Social Pharmacy and Epidemiology, Division of Social Pharmacy and Public Health, Showa Pharmaceutical University, Machida-shi, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6958-7864","authenticated-orcid":false,"given":"Azusa","family":"Hara","sequence":"additional","affiliation":[{"name":"Laboratory of Social Pharmacy and Epidemiology, Division of Social Pharmacy and Public Health, Showa Pharmaceutical University, Machida-shi, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Nakano","sequence":"additional","affiliation":[{"name":"Department of Multicenter Collaboration, Center for Clinical Research and Development, National Center for Child Health and Development, Setagaya-ku, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiji","family":"Mitsui","sequence":"additional","affiliation":[{"name":"Department of Multicenter Collaboration, Center for Clinical Research and Development, National Center for Child Health and Development, Setagaya-ku, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Deguchi","sequence":"additional","affiliation":[{"name":"Department of Multicenter Collaboration, Center for Clinical Research and Development, National Center for Child Health and Development, Setagaya-ku, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7641-4566","authenticated-orcid":false,"given":"Seiko","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Department of Multicenter Collaboration, Center for Clinical Research and Development, National Center for Child Health and Development, Okura, Setagaya-ku, Tokyo 157-8535, Japan"},{"name":"Laboratory of Social Pharmacy and Epidemiology, Division of Social Pharmacy and Public Health, Showa Pharmaceutical University, Machida-shi, Tokyo, Japan"},{"name":"Pharmacoepidemiology, Faculty of Pharmaceutical Sciences, Teikyo Heisei University, Nakano-ku, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-008-0123-3"},{"key":"e_1_3_4_3_2","volume-title":"Japan College of Rheumatology guideline for the treatment of juvenile idiopathic arthritis 2024\u201325","author":"Japan College of Rheumatology","year":"2025","unstructured":"Japan College of Rheumatology. Japan College of Rheumatology guideline for the treatment of juvenile idiopathic arthritis 2024\u201325. Tokyo, Japan: Medical View Sha, 2025 [in Japanese]."},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/road098"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16691"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15185"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00883-4"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2015.05.003"},{"key":"e_1_3_4_9_2","first-page":"59","article-title":"Drug- and herb-induced liver injury in clinical and translational hepatology: causality assessment methods, quo vadis?","volume":"1","author":"Teschke R","year":"2013","unstructured":"Teschke R, Eickhoff A, Schulze J. Drug- and herb-induced liver injury in clinical and translational hepatology: causality assessment methods, quo vadis? J Clin Transl Hepatol 2013; 1: 59\u201374.","journal-title":"J Clin Transl Hepatol"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-012-2136-8"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tox.2021.152840"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v9.i26.1092"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(99)70371-9"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090826"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/1091581817721675"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03754.x"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-013-0132-9"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/ped.15847"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-007-0625-4"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000001547"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.07.029"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2302"},{"key":"e_1_3_4_23_2","article-title":"Self controlled case series methods: an alternative to standard epidemiological study designs","volume":"354","author":"Petersen I","year":"2016","unstructured":"Petersen I, Douglas I, Whitaker H. Self controlled case series methods: an alternative to standard epidemiological study designs. BMJ 2016; 354: i4515.","journal-title":"BMJ"},{"key":"e_1_3_4_24_2","unstructured":"National Center for Child Health and Development. Pediatric medical information collection system https:\/\/pharma-net.ncchd.go.jp\/en\/ (accessed 16 April 2024)."},{"key":"e_1_3_4_25_2","first-page":"52","article-title":"Trends in health information and communication standards in Japan","volume":"69","author":"Kimura E","year":"2020","unstructured":"Kimura E, Ueno S. Trends in health information and communication standards in Japan. J Natl Inst Public Health 2020; 69: 52\u201362.","journal-title":"J Natl Inst Public Health"},{"key":"e_1_3_4_26_2","first-page":"1117","article-title":"Reference intervals of clinical tests in children determined by a latent reference value extraction method","volume":"112","author":"Tanaka T","year":"2008","unstructured":"Tanaka T, Yamashita A, Ichihara K. Reference intervals of clinical tests in children determined by a latent reference value extraction method. J Jpn Pediatr Soc 2008; 112: 1117\u20131132 [in Japanese].","journal-title":"J Jpn Pediatr Soc"},{"key":"e_1_3_4_27_2","unstructured":"Ministry of Health Labour and Welfare. Manual for serious adverse reaction disease manual drug-induced liver injury April 2008 (Revised September 2019) https:\/\/www.mhlw.go.jp\/topics\/2006\/11\/dl\/tp1122-1i01_r01.pdf (accessed 15 September 2024) [in Japanese]."},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26175"},{"key":"e_1_3_4_29_2","article-title":"The reporting of studies conducted using observational routinely-collected health data statement for pharmacoepidemiology (RECORD-PE)","volume":"363","author":"Langan SM","year":"2018","unstructured":"Langan SM, Schmidt SA, Wing K, et al. The reporting of studies conducted using observational routinely-collected health data statement for pharmacoepidemiology (RECORD-PE). BMJ 2018; 363: k3532.","journal-title":"BMJ"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.094474"},{"key":"e_1_3_4_31_2","article-title":"Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis","volume":"2013","author":"Shea B","year":"2013","unstructured":"Shea B, Swinden MV, Tanjong Ghogomu ET, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev 2013; 2013: CD000951.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1177\/2042098618792502"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.2217\/pgs-2021-0064"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.2217\/pgs-2022-0074"}],"container-title":["Therapeutic Advances in Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20420986251392451","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20420986251392451","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20420986251392451","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:41:09Z","timestamp":1777592469000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20420986251392451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":33,"alternative-id":["10.1177\/20420986251392451"],"URL":"https:\/\/doi.org\/10.1177\/20420986251392451","relation":{},"ISSN":["2042-0986","2042-0994"],"issn-type":[{"value":"2042-0986","type":"print"},{"value":"2042-0994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]},"article-number":"20420986251392451"}}